Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Anti-InflammatoryEnrolling Location: USA

    Phase 2 study of GS-5745 in adults with CF , protocol number Gilead GS-US-404-1808

    This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the anti-inflammatory drug GS-5745 and will use a placebo control.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirements

    • FEV1% Predicted:

      40 to 80%

    • Number of Visits:

      6

    • Length of Participation:

      24 weeks

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    Porcine viral antibody point prevalence study in people with CF taking pancreatic enzymes , protocol number AbbieVie JSPP-12-01

    This study is taking place at multiple care centre across the US. It will look at the prevalence of antibodies to hepatitis E virus (HEV) and other selected porcine viruses in people with cystic fibrosis who are receiving pancreatic enzyme replacement therapy (PERT).

    • Age:

      2 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      1

    • Length of Participation:

      1 day

    Contact us about this clinical Trial >
  • Anti-InflammatoryClosed to enrollment Location: USA

    Phase 2 study of JBT-101 in people with CF , protocol number Corbus JBT101-CF-001

    This study is taking place at multiple centres across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug JBT-101, as well as how the body processes the drug, in adults with CF.

    • Age:

      18 - 65 years

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      8

    • Length of Participation:

      127 days

    Contact us about this clinical Trial >
  • Anti-InflammatoryClosed to enrollment Location: USA

    KB001-A in people with CF and Pseudomonas aeruginosa , protocol number KaloBios KB001-05

    This study took place at multiple care centres across the U.S. It looked to see whether the use of KB001A in people with CF who have Pseudomonas aeruginosa delays the need for antibiotic drugs.

    • Age:

      12-50 Years

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40-100%

    • Number of Visits:

      10

    • Length of Participation:

      20 weeks

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis , protocol number NARKEW07A0

    This study will look at whether using abdominal ultrasounds predicts the progression of liver disease in children with CF.

    • Age:

      3 Years to 12 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      5

    • Length of Participation:

      5 years

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    Genetic Modifiers of Cystic Fibrosis: Sibling Study , protocol number NCT00037778

    The purpose of the study was to find genetic and environmental factors effecting the variability in nutritional outcomes seen in people with CF.

    • Age:

      No age limit

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      0

    • Length of Participation:

      0

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    OPTIMISE: Phase 3 study of tobramycin solution for inhalation with and without azithromycin , protocol number OPTIMISE-IP-12

    This study is taking place at multiple care centers across the US. It will compare the effects of treatment with tobramycin solution for inhalation with and without azithromycin. It is for people with CF who have their first isolation of Pseudomonas aeruginosa from a respiratory culture.

    • Age:

      6 Months to 18 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      8

    • Length of Participation:

      18 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: USA

    Phase 1b safety study of QR-010 in adults with CF , protocol number ProQR PQ-101-001

    This study is taking place at multiple care centers across the U.S. It will test the safety and tolerability of the drug QR-010 in adults with cystic fibrosis. It will also look at how the body processes the drug..

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      60 to 90%

    • Number of Visits:

      9

    • Length of Participation:

      28 days

    Contact us about this clinical Trial >
  • Mucociliary ClearanceClosed to enrollment Location: USA

    Clearing Lungs With ENAC Inhibition in Cystic Fibrosis (CLEAN-CF) , protocol number Parion PS-G201

    This trail will look at the safety of the drug P-1037 and its effectiveness in combination with the drug hypertonic saline. The trail is estimated to last 5 weeks. It is for people with CF age 12 years and older.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      4

    • Length of Participation:

      5 weeks

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: USA

    PROSPECT , protocol number PROSPECT-OB-14

    This two-part study is taking place at multiple care centres across the US. It will aim to identify biomarkers that show CFTR function and disease progression. It will also look at the effect of lumacafter/ivacaftor on those who are prescribed treatment.

    • Age:

      6 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      8

    • Length of Participation:

      15 months

    Contact us about this clinical Trial >
  • Displaying results 91-100 (of 130)
     |<  <  4 - 5 - 6 - 7 - 8 - 9 - 10 - 11 - 12 - 13  >  >|